Gastric Inhibitory Polypeptide Analogues: Do They Have a Therapeutic Role in Diabetes Mellitus Similar to That of Glucagon-Like Peptide-1?

Author： Holst J.J.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.16, Iss.3, 2002-01, pp. : 175-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide: Potential Applications in Type 2 Diabetes Mellitus

By Meier J.J.  

BioDrugs, Vol. 17, Iss. 2, 2003-01 ,pp. : 93-102

Adis International

Access to resources Recommend Favorite

Therapeutic Potential of Human Amylin Analogues in Diabetes Mellitus

By Cooper G.J.S.  

BioDrugs, Vol. 10, Iss. 1, 1998-07 ,pp. : 1-9

Adis International

Access to resources Recommend Favorite

Iliopsoas abscess in adolescents with type 1 diabetes mellitus

By  

Clinical Case Reports, Vol. 3, Iss. 7, 2015-07 ,pp. : 638-642

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spotlight on Insulin Detemir in Type 1 and 2 Diabetes Mellitus

By Chapman Therese M.   Perry Caroline M.  

BioDrugs, Vol. 19, Iss. 1, 2005-01 ,pp. : 67-69

Adis International

Access to resources Recommend Favorite

Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus

By Vilsbøll Tina   Knop Filip K.  

BioDrugs, Vol. 22, Iss. 4, 2008-01 ,pp. : 251-257

Adis International

Access to resources Recommend Favorite